CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Disulfiramdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01944371
NCT01944371Phase 2Completed
CompareCT.gov

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

University of California, San Francisco·interventional·Posted Sep 17, 2013·Updated May 5, 2020

In Brief

A Phase 2 clinical trial evaluating Disulfiram for HIV and Human Immunodeficiency Virus. Completed, enrolled 30 participants across 2 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Human Immunodeficiency Virus
CountriesAustralia, United States
CollaboratorsMonash University, amfAR, The Foundation for AIDS Research, National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 17, 2013
Enrollment StartSep 1, 2013
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.8 years ago

Interventions

Disulfiramdrug

This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.